Compare NRDY & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRDY | OCGN |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 387.3M |
| IPO Year | N/A | N/A |
| Metric | NRDY | OCGN |
|---|---|---|
| Price | $1.37 | $1.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $1.25 | ★ $7.00 |
| AVG Volume (30 Days) | 1.4M | ★ 3.1M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $177,867,000.00 | $5,370,000.00 |
| Revenue This Year | N/A | $32.40 |
| Revenue Next Year | $4.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.26 |
| 52 Week Low | $0.77 | $0.52 |
| 52 Week High | $2.18 | $1.90 |
| Indicator | NRDY | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.09 | 59.94 |
| Support Level | $1.34 | $1.18 |
| Resistance Level | $1.49 | $1.26 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 76.21 | 92.08 |
Nerdy Inc is a curated direct-to-consumer platform for live online learning. Its proprietary platform leverages technology, including artificial intelligence ("AI"), to connect students, users, parents, guardians, and purchasers of all ages to tutors, instructors, subject matter experts, educators, and other professionals. The company provides learning experiences across numerous subjects and multiple formats, including one-on-one instruction, small group tutoring, large format classes, tutor chat, essay review, adaptive assessments, and self-study tools. The company generates revenue by selling services to learners and institutions for one-on-one instruction and small group tutoring.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").